Online Exclusives

Online Exclusives

From ASH 2014: Promising Phase 2 Results with ACE-536 in β-Thalassemia

SAN FRANCISCO — ACE-536, a recombinant fusion protein containing modified activin receptor type IIB and IgG Fc, has shown promising results in the treatment...

From ASH 2014: AHCT Should Be Standard of Care for HIV-Associated Lymphoma

SAN FRANCISCO — Results from a multi-institutional trial presented at ASH 2014 debunk common myths that HIV-positive patients with lymphoma might not be suitable for...

American Society of Hematology Releases Statement on Congressional Funding

The American Society of Hematology (ASH) released a statement from President Charles S. Abrams, MD, congratulating Congress on the passage of a short-term resolution to fund...

Donor Age and Sex May Affect Outcomes for Patients Receiving Red Blood Cell Transfusions

According to a study published in JAMA Internal Medicine, red blood cell (RBC) transfusions from donors who are younger or female are associated with...

FDA Approves Obinutuzumab for Follicular Lymphoma

The U.S. Food and Drug Administration (FDA) has approved obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with...

Study Finds Overprotective Parents Play a Key Role in Children’s Sickle Cell Disease Outcomes

Children with sickle cell disease (SCD) whose parents reported catastrophizing and protective parenting behaviors were at an increased risk for severe functional disability, according...

FDA Grants Orphan Designation to Ublituximab and TGR-1202 for DLBCL

The U.S. Food and Drug Administration granted orphan drug designation for ublituximab (an anti-CD20 monoclonal antibody) in combination with TGR-1202 (a next generation phosphoinositide...

Researchers Link Obesity-Associated Protein With AML

Preclinical research indicates that the fat mass- and obesity-associated protein FTO (an N6-methyladenosine ) is involved in the development of acute myeloid leukemia (AML)...

FDA Expands Indication for Hemophilia A Drug

The U.S. Food and Drug Administration (FDA) approved an expanded indication for Adynovate® (antihemophilic factor , PEGylated) for pediatric patients (<12 years) with hemophilia...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.